目的 探讨卡介菌多糖核酸联合异丙托溴铵治疗支气管哮喘的临床疗效。方法 选取2016年4月—2017年4月在南阳市中心医院治疗的支气管哮喘患者74例，随机分为对照组（37例）和治疗组（37例）。对照组雾化吸入异丙托溴铵气雾剂，2揿/次，2次/d；治疗组在对照组基础上静脉滴注卡介菌多糖核酸注射液，1 mL/次，3次/周。两组患者均治疗4周。观察两组患者临床疗效，比较治疗前后两组患者肺功能、血清学指标、临床症状评分和PAQLQ各维度评分。结果 治疗后，对照组和治疗组临床总有效率分别为81.08%和97.30%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者1秒用力呼气容积（FEV1）、用力肺活量（FVC）、最大呼气流速（PEF）均显著升高（P<0.05）；且治疗组患者上述肺功能指标水平明显高于对照组（P<0.05）。治疗后，两组患者血清IL-4、基质金属蛋白酶-9（MMP-9）和基质金属蛋白酶天然抑制剂-1（TIMP-1）水平均显著降低，IL-2和IFN-γ水平显著升高，同组比较差异具有统计学意义（P<0.05）；且治疗组患者血清学指标显著优于对照组（P<0.05）。治疗后，两组患者胸闷、喘息、咳嗽和哮鸣音等评分均明显降低（P<0.05）；且治疗组比对照组降低更显著（P<0.05）。治疗后，两组PAQLQ各维度评分均明显升高（P<0.05）；且治疗组比对照组升高更显著（P<0.05）。结论 卡介菌多糖核酸联合异丙托溴铵治疗支气管哮喘可有效改善患者临床症状，利于患者肺功能改善。

objective To investigate the clinical efficacy of BCG polysaccharide and nucleic acid combined with ipratropium bromide in treatment of bronchial asthma. Methods Patients (74 cases) with bronchial asthma in Nanyang City Central Hospital from April 2016 to April 2017 were randomly divided into control (37 cases) and treatment (37 cases) groups. Patients in the control group were atomization inhalation administered with Ipratropium Bromide Aerosol, 2 presses/time, twice daily. Patients in the treatment group were iv administered with BCG Polysaccharide and Nucleic Acid Injection on the basis of the control group, 1 mL/time, three times weekly. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the pulmonary function, serum markers, the clinical symptom scores and PAQLQ scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.08% and 97.30%, respectively, and there were differences between two groups (P < 0.05). After treatment, the FEV1, FVC and PEF in two groups were significantly increased (P < 0.05). And these pulmonary function indexes levels in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the IL-4, MMP-9 and TIMP-1 levels in two groups were significantly decreased, but the IL-2 and IFN-γ levels were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these serum markers in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the chest tightness, wheezing, coughing and wheezing scores in two groups were significantly decreased (P < 0.05). And these clinical symptom scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the PAQLQ scores in two groups were significantly increased (P < 0.05). And these PAQLQ scores in the treatment group increased more significantly than those in the control group (P < 0.05). Conclusion BCG polysaccharide and nucleic acid combined with ipratropium bromide in treatment of bronchial asthma can effectively improve the clinical symptoms and lung function.